CVS Health (CVS) The UBS 2016 Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
The UBS 2016 Global Healthcare Conference summary
4 Nov, 2026Integrated strategy and market positioning
Strategy centered on addressing the cost-quality-access challenge through integrated assets intended to improve outcomes and lower costs for patients, payers, and providers.
Channel-agnostic programs, specialty capabilities, purchasing scale, retail clinics, and long-term care services positioned as differentiated offerings for healthcare partners.
Caremark managed claims grew more than 57% since 2008, while enterprise dispensing volume rose more than 70% over the same period.
Enterprise dispensing share of Caremark business increased 700 bps since 2008, adding $7B in dispensed revenue, including $2B in 2015.
PBM performance and client wins
2016 PBM gross new business wins reached $15.2B; client retention was 97.3%, producing $13.1B of net new business.
2016 wins included $1.8B from 91 new employer clients; about 83% of gross wins came from health plans, including Aetna Coventry Medicare Part D lives.
Client prescription drug trend fell from 11.8% in 2014 to 5% in 2015; proactive cost management cut trend by more than 50% despite record drug price increases.
2017 selling season was off to a good start despite CalPERS and ERS contract losses; a quantitative update was planned for a later earnings call.
2015 enterprise dispensing exceeded 1.3B prescriptions and Caremark managed more than 1.1B claims, supporting procurement scale and manufacturer negotiations.
Specialty, retail, and clinic growth
Specialty market projected to exceed $200B by 2020; specialty revenue was more than $40B in 2015 and projected at ~$49B in 2016.
CVS Specialty dispensed revenue grew at more than 32% CAGR from 2012 to 2016, versus 19% industry CAGR; offerings included Specialty Connect and rare-disease nursing support.
Retail pharmacy growth was twice the overall retail market; nearly 44% of retail growth over the prior two years came from share gains with other payers.
Medication possession ratios for three chronic conditions were ~650 bps above the top three retail competitors; Target acquisition added more than 1,600 pharmacies and 80 clinics.
Target locations were expected to convert to CVS Pharmacy and MinuteClinic brands by end of summer 2016; MinuteClinic operated more than 1,100 clinics across 33 states and Washington, D.C.
Latest events from CVS Health
- Separation aims to unlock standalone growth while preserving investment-grade balance sheets.CVS
8th Annual Wolfe Research Healthcare Conference - Care delivery expansion and post-deleveraging capital choices shape the forward strategy.CVS
30th Annual Credit Suisse Healthcare Conference - PBM cost controls, health plan growth and integrated care underpin the outlook.CVS
The 2016 Morgan Stanley Global Healthcare Conference - Integrated pharmacy and clinical programs aim to improve outcomes and reduce care costs.CVS
UBS Global Healthcare Conference 2017 - Signify bolsters in-home care and value-based strategy amid stable utilization.CVS
Morgan Stanley 20th Annual Global Healthcare Conference - Aetna integration targets >$750M in 2020 synergies and broader medical-cost savings.CVS
JP Morgan 37th Annual Healthcare conference - Cost savings and payer partnerships support long-term growth and shareholder returns.CVS
Investor Day 2016 - A $77B Aetna deal targets integrated care and $750M in year-two synergies.CVS
M&A announcement - FY18 operating profit growth guided to 1%–4%, tempered by PBM and deal-related headwinds.CVS
Guidance